Loveride was an antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loveride was a NNRTI that entered phase III clinical trials in the late 1990’s but failed to gain marketing approval because of poor potency. It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate Loveride (e.g., CAESAR and AVANTI), because in those trials Loveride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to all NNRTI’s.